Table 1.
Characteristics of patients in systemic chemotherapy studies.
| Reference | Setting | Randomization | Regimens of Chemotherapy | Number of Patients | Age (Range) | Mean Follow-Up | Risk Factors |
|---|---|---|---|---|---|---|---|
| Kanemitsu et al., 2021 [33] | Phase II/III | YES | FOLFOX6 vs. SA | FOLFOX6 (n = 151), SA (n = 149) | FOLFOX6, 63 y (56–69); SA, 65 y (58–69) | 59.2 mo (IQR 26.5–95.3) | Timing, number and diameter of CRLMs, R0 resections, LNM |
| Kokudo et al., 2021 [34] | Phase III | YES | UFT/LV vs. SA | UFT/LV (n = 90), SA (n = 90) | UFT/LV, 62.2 y (SD 8.5); SA, 64.5 y (SD 9.2) | 7.36 y (6.93–7.87) | Timing, number and diameter of CRLMs, R0 resections, LNM |
| Satake et al., 2021 [35] | Phase II | NO | CAPOX | 28 | 69.5 y (39–82) | 64.3 mo (26.3–87.5) | Timing, number and diameter of CRLMs, R0 resections, LNM |
| Sugimoto et al., 2021 [36] | Retrospective | NO | Oxaliplatin-based vs. fluoropyrimidine regimen | Oxaliplatin-based (n = 47), fluoropyrimidine regimen (n = 47) | Oxaliplatin-based, 61 y (32–78); Fluoropyrimidine, 67 y (37–85) | 64.5 mo (7.5–163.1) | Timing, number and diameter of CRLMs, R0 resections, LNM, CEA levels |
| Kobayashi et al., 2019 [37] | Retrospective | NO | AC (FOLFOX, FOLFIRI, CapeOx, 5-FU/LV, UFT/LV, S-1, HAI, doxifluridine) vs. SA | AC (n = 771), SA (n = 374) | AC < 65 y (n = 411); ≥65 y (n = 360); SA, <65 y (n = 145); ≥65 y (n = 229) | 79.4 mo | Timing, number and diameter of CRLMs, R0 resections, LNM, CEA levels |
| Nishioka et al., 2017 [38] | Retrospective | NO | UFT/LV or oxaliplatin-based chemotherapy vs. SA | AC (n = 105), SA (n = 104) | AC, 65 y (36–88) SA: 63 y (35–74) | AC: 48 mo, SA: 28 mo | Timing, number and diameter of CRLMs, R0 resections, LNM, CEA levels |
| Kato et al., 2015 [39] | Phase II | NO | S-1 | 60 | 64 y (43–78) | 41 mo (5–57) | Timing, number and diameter of CRLMs, R0 resections, LNM, CEA levels |
| Hsu et al., 2013 [40] | Retrospective | NO | 5-FU/LV vs. FOLFIRI/IFL vs. FOLFOX | 5-FU/LV (n = 25) FOLFIRI/IFL (n = 21), FOLFOX (n = 26) | 58 y (26–76) | 38.8 mo | Timing, number and diameter of CRLMs, R0 resections, CEA levels |
| Turan et al., 2013 [41] | Retrospective | NO | BEV vs. No BEV | BEV (n = 87), No BEV (n = 117) | 56 y (24–82) | 27 mo | Timing, number and diameter of CRLMs, R0 resections, LNM |
| Sakamoto et al., 2012 [42] | Single-arm | NO | FOLFOX4/modified FOLFOX6 | 24 | 58 yr (25–77) | 48.4 mo | Timing, number and diameter of CRLMs, LNM |
| Kemeny et al., 2011 [43] | Phase II | YES | BEV vs. No BEV | BEV (n = 35), No BEV (n = 38) | Bev, ≥60 y (n = 10); <60 y (n = 25); No Bev, ≥60 y (n = 11) <60 y (n = 27) | 30 mo | Timing, number and diameter of CRLMs, R0 resections, LNM, CEA levels, KRAS status |
| Kim et al., 2011 [44] | Retrospective | NO | FOLFOX4/modified FOLFOX6 | 60 | 55 y (31–73) | 33.1 mo (95% CI: 4.1–108.5) | Timing, number and diameter of CRLMs, R0 resections, LNM, CEA levels |
| Liu et al., 2010 [45] | Retrospective | NO | FOLFOX/FOLFIRI vs. 5- FU/LV | FOLFOX/FOLFIRI (n = 31), 5-FU/LV (n = 19) | 70 y (47–85) | 35.5 mo (10–96) | Timing, number and diameter of CRLMs, R0 resections, CEA levels |
| Ychou et al., 2009 [46] | Phase III | YES | FOLFIRI vs. 5-FU/LV | FOLFIRI (n = 153), 5-FU/LV (n = 153) | FOLFIRI, 63 y (27–75); 5-FU/LV, 61 y (34–76) | FOLFIRI; 41.7 mo, LV5-FU; 42.4 mo | Timing and number of CRLMs, R0 resections, |
| Kim et al., 2009 [47] | Retrospective | NO | Oxaliplatin (group 1) vs. irinotecan (group 2) vs. fluoropyrimidine alone (group 3) regimens | group 1 (n = 58), group 2 (n = 48), group 3 (n = 50) | group 1, 61 y (25–78) group 2, 57 y (33–72) group 3, 61 y (32–77) | 44 mo (18.4–86.9) | Number and diameter of CRLMs, R0 resections, LNM CEA levels |
| Portier et al., 2006 [48] | Phase III | YES | 5-FU + folinic acid vs. SA | AC (n = 86), SA (n = 85) | AC, <55 y (n = 16); 55–64 y (n = 34); >65 y (n = 36) SA, <55 y (n = 15) 55–64 y (n = 37); >65 y (n = 33) | 87.4 mo (SE = 5.8) | Timing, number and diameter of CRLMs, R0 resections, CEA levels |
| Mackay et al., 2005 [49] | Phase II | NO | Irinotecan | 29 | 57 y (40–71) | 27.9 mo (17.4–45.7) | Timing and number of CRLMs |
| Gardini et al., 2004 [50] | Clinical trial | NO | TIL+IL-2 vs. SA | TIL+IL-2 (n = 14), SA (n = 22) | TIL+IL-2, 57 y (40–70) SA, 57 y (37–70) | 42 mo | Number and diameter of CRLMs, CEA levels |
Abbreviations: 5-FU: 5-fluorouracil; 5-FU/LV: 5-fluorouracil/leucovorin; BEV: bevacizumab; CAPOX: capecitabine plus oxaliplatin; FOLFIRI: folinic acid, 5-FU plus irinotecan; FOLFOX: 5-FU/LV plus oxaliplatin; S-1: tegafur plus gimeracil and oteracil; TIL+IL2: tumor-infiltrating lymphocytes plus interleukin-2; UFT/LV: uracil/tegafur plus LV; AC: adjuvant chemotherapy; SA: surgery alone; CEA: carcinoembryonic antigen; LNM: lymph node metastasis; y: year; mo: months.